Myriad Genetics, Inc. (MYGN)
| Previous close | 18.60 |
| Open | 18.54 |
| Bid | 18.68 x 100 |
| Ask | 18.74 x 100 |
| Day's range | 18.37 - 18.73 |
| 52-week range | 13.82 - 24.21 |
| Volume | |
| Avg. volume | 615,166 |
| Market cap | 1.692B |
| Beta (5Y monthly) | 1.98 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.18 |
| Earnings date | 01 May 2024 - 06 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 23.91 |
ZacksWill Myriad Genetics (MYGN) Report Negative Q1 Earnings? What You Should Know
Myriad (MYGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GlobeNewswireNearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor
80% of people diagnosed with anxiety, depression report losing years or decades of timeSALT LAKE CITY, April 17, 2024 (GLOBE NEWSWIRE) -- An astonishing 44% of Americans feel they have lost time in their lives due to poor mental health. That number jumps to nearly 80% for those diagnosed with anxiety and/or depression, according to the latest GeneSight Mental Health Monitor, a nationwide survey from Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine. Of those
GlobeNewswireNew Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen
SALT LAKE CITY, April 16, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that Prenatal Diagnosis has published a study1 demonstrating exceptional positive predictive value (PPV) for 22q11.2 microdeletion screening using Myriad’s prenatal cell-free DNA (pcfDNA) screen, Prequel®, which incorporates fetal fraction amplification. Prior studies from other commercial pcfDNA laboratories have reported a broad range of
